Cargando…

Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer

BACKGROUND: Oncogenic KRAS mutations are prevalent in human cancers, but effective treatment of KRAS-mutant malignancies remains a major challenge in the clinic. Increasing evidence suggests that aberrant metabolism plays a central role in KRAS-driven oncogenic transformation. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Zhang, Liang, Shun-Qing, Zhao, Liang, Yang, Haitang, Marti, Thomas M., Hegedüs, Balazs, Gao, Yanyun, Zheng, Bin, Chen, Chun, Wang, Wenxiang, Dorn, Patrick, Kocher, Gregor J., Schmid, Ralph A., Peng, Ren-Wang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762933/ https://www.ncbi.nlm.nih.gov/pubmed/35039048 http://dx.doi.org/10.1186/s13046-022-02240-5

Ejemplares similares

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer
por: Yang, Zhang, et al.
Publicado: (2021)

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
por: Yang, Haitang, et al.
Publicado: (2019)

The roles of NOP56 in cancer and SCA36
por: Zhao, Shimin, et al.
Publicado: (2023)

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
por: Yang, Haitang, et al.
Publicado: (2019)

Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
por: Xu, Duo, et al.
Publicado: (2019)

High-resolution structure of eukaryotic Fibrillarin interacting with Nop56 amino-terminal domain
por: Höfler, Simone, et al.
Publicado: (2021)

Nucleolar Division in the Promastigote Stage of Leishmania major Parasite: A Nop56 Point of View
por: Nepomuceno-Mejía, Tomás, et al.
Publicado: (2018)

A nop56 Zebrafish Loss-of-Function Model Exhibits a Severe Neurodegenerative Phenotype
por: Quelle-Regaldie, Ana, et al.
Publicado: (2022)

Repeat expansions in NOP56 are a cause of spinocerebellar ataxia Type 36 in the British population
por: Lam, Tanya, et al.
Publicado: (2023)

A Breakthrough Brought about by Targeting KRAS(G12C): Nonconformity Is Punished
por: Ning, Wenjuan, et al.
Publicado: (2022)

Repeats expansions in ATXN2, NOP56, NIPA1 and ATXN1 are not associated with ALS in Africans
por: Nel, Melissa, et al.
Publicado: (2021)

Identification of Malignancy in PAP Smear Samples Using the CGB3 and NOP56 Genes as Methylation Markers
por: Singh, Palak, et al.
Publicado: (2022)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

Malignant pleural mesothelioma co-opts BCL-X(L) and autophagy to escape apoptosis
por: Xu, Duo, et al.
Publicado: (2021)

MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2023)

A Chinese SCA36 pedigree analysis of NOP56 expansion region based on long-read sequencing
por: Zou, Jinlong, et al.
Publicado: (2023)

The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer
por: Floc'h, Nicolas, et al.
Publicado: (2012)

Association between promoter methylation and gene expression of CGB3 and NOP56 in HPV-infected cervical cancer cells
por: Singh, Palak, et al.
Publicado: (2022)

Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2022)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer
por: Yang, Haitang, et al.
Publicado: (2020)

Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations
por: Fritsche-Guenther, Raphaela, et al.
Publicado: (2018)

mTOR modulates the antibody response to provide cross-protective immunity to lethal influenza infections
por: Keating, Rachael, et al.
Publicado: (2013)

Parkinson’s disease: no NOP, new hope
por: Arcuri, Ludovico, et al.
Publicado: (2016)

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations
por: Rittler, Dominika, et al.
Publicado: (2020)

A Proteomic Screen for Nucleolar SUMO Targets Shows SUMOylation Modulates the Function of Nop5/Nop58
por: Westman, Belinda J., et al.
Publicado: (2010)

Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)
por: Gao, Yanyun, et al.
Publicado: (2021)

CD8(+) T cell survival in lethal fungal sepsis was ameliorated by T-cell-specific mTOR deletion
por: Wang, Hao, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma
por: Xu, Duo, et al.
Publicado: (2018)

The Clinical and Polynucleotide Repeat Expansion Analysis of ATXN2, NOP56, AR and C9orf72 in Patients With ALS From Mainland China
por: Hou, Xiaorong, et al.
Publicado: (2022)

Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality
por: Zhang, Wenfeng, et al.
Publicado: (2019)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

CD8(+) T cell survival in lethal fungal sepsis was ameliorated by T-cell-specific mTOR deletion: Erratum
por: Wang, Hao, et al.
Publicado: (2022)

The Translational Regulation in mTOR Pathway
por: Yang, Miaomiao, et al.
Publicado: (2022)

Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer
por: Wang, Limei, et al.
Publicado: (2021)

Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104
por: Li, Fan, et al.
Publicado: (2020)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Burkitt’s lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis
por: Cowling, Victoria H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_debmuehckm5papqkf66saj3f83